We had an in-depth interview with James Lanthier, CEO of Mindset Pharma – one of the more interesting psychedelic stocks. He shared his perspective on: Treatment Resistant Depression (TRD), their plans to synthesize psilocybin, upcoming catalysts and why capital markets are increasing their interest in psychedelic firms.
The opinions provided in this article are those of the author and do not constitute investment advice. Readers should assume that the author and/or employees of Capital 10X hold positions in the company or companies mentioned in the article. For more information, please see our Content Disclaimer.